{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T09:33:51Z","timestamp":1758188031903,"version":"3.44.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017634","name":"Henan University of Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This study systematically evaluates the efficacy and safety of Shufeng Jiedu Capsules in treating respiratory diseases with wind-heat syndrome patterns, providing clinical guidance and a reference for developing new \u201csyndrome-dominating disease management\u201d medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic search of CNKI, Wanfang, VIP, SinoMed, PubMed, Cochrane Library, Embase, Web of Science, and trial registries identified randomized controlled trials (RCTs) assessing Shufeng Jiedu Capsules for wind-heat syndrome respiratory diseases (from inception to December 2024). Two researchers independently screened studies and extracted data using predefined criteria. Methodological quality was assessed using the Cochrane Risk of Bias tool. RevMan 5.3 and Stata 18 were used for data analysis, and evidence quality was graded using the GRADE system.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-five RCTs involving 2681 patients were included, with 1339 in the experimental group and 1342 in the control group. The GRADE assessment indicated predominantly low or very low evidence certainty, mainly due to methodological flaws such as unclear allocation concealment, lack of blinding, and absence of protocol registration, which increased the risk of bias. Meta-analysis showed that Shufeng Jiedu Capsule combined with conventional biomedical therapy outperformed biomedical therapy alone. It improved the effective rate of traditional Chinese medicine syndromes (risk ratio [RR] = 1.17, 95% CI 1.10 to 1.24, <jats:italic>P<\/jats:italic> &amp;lt; 0.00001) and shortened the resolution time of cough (mean difference [MD] = \u22120.97, 95% CI \u22121.09 to \u22120.85, <jats:italic>P<\/jats:italic> &amp;lt; 0.00001) and phlegm (MD = \u22120.48, 95% CI \u22120.96 to \u22120.17, <jats:italic>P<\/jats:italic> = 0.002). These outcomes were supported by high-quality GRADE evidence. Moderate-quality evidence supported improvements in imaging absorption rates (RR = 1.15, 95% CI 1.06 to 1.25, <jats:italic>P<\/jats:italic> = 0.0009) and shorter resolution time for pulmonary rales (MD = \u22121.48, 95% CI \u22122.86 to \u22120.10, <jats:italic>P<\/jats:italic> = 0.04). In contrast, apparent benefits in the clinical effective rate (RR = 1.16, 95% CI 1.12 to 1.19, <jats:italic>P<\/jats:italic> &amp;lt; 0.00001), fever resolution time (MD = \u22121.31, 95% CI \u22122.07 to \u22120.55, <jats:italic>P<\/jats:italic> = 0.0007), C-reactive protein levels (standardized MD [SMD] = \u22120.99, 95% CI \u22121.55 to \u22120.43, <jats:italic>P<\/jats:italic> = 0.0005), and procalcitonin levels (SMD = \u22122.06, 95% CI \u22123.62 to \u22120.49, <jats:italic>P<\/jats:italic> = 0.01) were based on low or very low certainty evidence. These results should be interpreted cautiously and require confirmation in rigorously designed trials. There was no significant difference in the incidence of adverse events between groups (RR = 0.88, 95% CI 0.34 to 2.31, <jats:italic>P<\/jats:italic> = 0.80). The adverse events were minor and controllable, and no serious adverse events were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Shufeng Jiedu Capsule combined with biomedicine may offer advantages in treating respiratory diseases with wind-heat syndrome. The adverse events were minor and controllable, and no serious adverse events were reported. However, the reliability of these findings is limited by low evidence certainty arising from methodological weaknesses in the included trials. High-quality, multicenter RCTs with rigorous methodology are essential to confirm these results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251017879<\/jats:ext-link>, identifier CRD420251017879.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1602563","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T05:30:37Z","timestamp":1758173437000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Shufeng Jiedu Capsules for treating wind-heat syndrome respiratory diseases: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Jia-Min","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gui-Xiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Long","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.19621\/j.cnki.11-3555\/r.2019.0921","article-title":"Clinical observation of shufeng jiedu capsule in the treatment of acute exacerbation of chronic obstructive pulmonary disease with wind-heat invading lung syndrome","volume":"27","author":"Chang","year":"2019","journal-title":"Chin. J. Folk. Ther."},{"key":"B2","first-page":"1171","article-title":"Effect of shufeng jiedu capsule on sTREM-1, YKL-40, SP-D, and fib in patients with acute exacerbation of chronic obstructive pulmonary disease","volume":"36","author":"Chen","year":"2021","journal-title":"Chin. J. Tradit. Chin. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.7507\/1672-2531.202201063","article-title":"Maternal protocol basket trial design under precision medicine model and its application in the field of traditional Chinese medicine","volume":"22","author":"Chen","year":"2022","journal-title":"Chin. J. Evidence-Based Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.3969\/j.issn.1673-7202.2020.22.014","article-title":"Effect of shufeng jiedu capsule on patients with acute exacerbation of chronic bronchitis with wind-heat invading lung syndrome","volume":"15","author":"Fei","year":"2020","journal-title":"World J. Tradit. Chin. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"9584703","DOI":"10.1155\/2017\/9584703","article-title":"Inhibition of Pseudomonas aeruginosa biofilm formation by traditional Chinese medicinal herb herba patriniae","volume":"2017","author":"Fu","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"B6","first-page":"7392","article-title":"Application exploration of basket trial design in clinical research of traditional Chinese medicine","volume":"36","author":"Gan","year":"2021","journal-title":"Chin. J. Traditional Chin. Med."},{"key":"B7","first-page":"194","article-title":"Modern pharmacology and new clinical applications of isatidis radix","volume":"14","author":"Gao","year":"2016","journal-title":"China Med. Guide"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.3969\/j.issn.1004-745X.2016.12.053","article-title":"Clinical observation of shufeng jiedu capsule combined with Western medicine in the treatment of acute exacerbation of chronic bronchitis","volume":"25","author":"Han","year":"2016","journal-title":"Emerg. Med. TCM."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.7501\/j.issn.0253-2670.2019.15.006","article-title":"Mechanism of anti-inflammatory and immunomodulatory effects of shufeng jiedu capsule based on network pharmacology","volume":"50","author":"Han","year":"2019","journal-title":"Chin. Traditional Herb. Drugs"},{"key":"B10","volume-title":"Clinical observation of shufeng jiedu capsule on patients with acute exacerbation of chronic obstructive pulmonary disease (wind-heat invading lung syndrome) and its effect on serum YKL-40, SP-D, STREM-1, and fib","author":"He","year":"2019"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.13192\/j.issn.1000-1719.2020.01.001","article-title":"State-target differentiation: a historical choice for traditional Chinese medicine transitioning from macro to precision","volume":"47","author":"He","year":"2020","journal-title":"Liaoning J. Traditional Chin. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s10753-011-9310-z","article-title":"Anti-inflammatory effect of resveratrol and polydatin by in vitro IL-17 modulation","volume":"35","author":"Lanzilli","year":"2012","journal-title":"Inflammation"},{"key":"B13","first-page":"558","article-title":"Based on the disease-syndrome combination model, we should pay attention to the diagnosis and treatment form of syndrome-based disease management","volume":"52","author":"Li","year":"2011","journal-title":"Chin. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.14035\/j.cnki.hljyy.2022.06.027","article-title":"Effect of shufeng jiedu capsule on clinical symptoms and CRP, ESR in patients with febrile upper respiratory tract infection","volume":"35","author":"Li","year":"2022","journal-title":"Heilongjiang Med. J."},{"key":"B15","volume-title":"Effect of shufeng jiedu capsule on serum levels of AQP-1, AQP-5, and CC16 in patients with acute exacerbation of chronic obstructive pulmonary disease (wind-heat invading lung and phlegm-heat obstructing lung syndrome)","author":"Li","year":"2023"},{"key":"B16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3969\/j.issn.1007-8517.2019.5.zgmzmjyyzz201905030","article-title":"Clinical observation of 40 cases of acute exacerbation of chronic obstructive pulmonary disease with wind-heat invading lung syndrome treated with integrated traditional Chinese and Western medicine","volume":"28","author":"Li","year":"2019","journal-title":"Chin. J. Ethnomed. Ethnopharm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3969\/j.issn.1004-745X.2022.07.030","article-title":"Observation on the efficacy of shufeng jiedu capsule in the adjuvant treatment of elderly patients with community-acquired pneumonia","volume":"31","author":"Li","year":"2022","journal-title":"Emerg. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.3969\/j.issn.1000-4718.2023.07.015","article-title":"Protective effect of phragmitis rhizoma aqueous extract on radiation-induced lung injury in mice","volume":"39","author":"Li","year":"2023","journal-title":"Chin. J. Pathophysiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3969\/j.issn.1009-0959.2023.07.015","article-title":"Clinical application value of shufeng jiedu capsule in patients with acute upper respiratory tract infections","volume":"25","author":"Li","year":"2023","journal-title":"Chin. Med. Her."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.19540\/j.cnki.cjcmm.20220211.501","article-title":"Clinical comprehensive evaluation of Chinese patent medicines using the EVIDEM framework","volume":"47","author":"Liao","year":"2022","journal-title":"China J. Chin. Mater. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"100836","DOI":"10.1016\/j.imr.2022.100836","article-title":"GRADE methods in traditional medicine","volume":"11","author":"Liu","year":"2022","journal-title":"Integr. Med. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.16333\/j.1001-6880.2015.07.023","article-title":"Experimental study on anti-inflammatory activity of Forsythia suspensa extract based on human respiratory epithelial cell inflammation model","volume":"27","author":"Liu","year":"2015","journal-title":"Nat. Prod. Res. Dev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.13288\/j.11-2166\/r.2022.01.016","article-title":"Clinical practice guideline on traditional Chinese medicine for influenza (2021)","volume":"63","author":"Liu","year":"2022","journal-title":"J. Tradit. Chin. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3969\/j.issn.1004-745X.2023.08.019","article-title":"Clinical observation of shufeng jiedu capsule in the treatment of acute exacerbation of chronic obstructive pulmonary disease complicated with type II respiratory failure","volume":"32","author":"Luo","year":"2023","journal-title":"Emerg. Med. TCM."},{"key":"B25","volume-title":"Guidelines for clinical research of new Chinese medicines (trial)","year":"2002"},{"key":"B26","first-page":"303","article-title":"National drug standards of the national medical products administration (revised) (approval document no.: ZGB2013-1-10)","volume":"6","year":"2014","journal-title":"Chin. Drug Stand."},{"key":"B27","unstructured":"Announcement of the NMPA on the conversion of 4 drugs including shufeng jiedu capsules to OTC drugs\n          \n          \n          2021"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.3969\/j.issn.1673-7202.2017.10.065","article-title":"Clinical application of shufeng jiedu capsule in the treatment of diseases","volume":"12","author":"Ou","year":"2017","journal-title":"World J. Tradit. Chin. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B30","first-page":"3224","article-title":"Clinical observation on the efficacy of shufeng jiedu capsule in the treatment of community-acquired pneumonia with wind-heat syndrome and its effect on cytokines","volume":"35","author":"Pan","year":"2020","journal-title":"China J. Traditional Chin. Med. Pharm."},{"key":"B31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.13412\/j.cnki.zyyl.20240422.001","article-title":"Meta-analysis and pharmacoeconomic evaluation of shufeng jiedu capsule in the treatment of acute exacerbation of chronic obstructive pulmonary disease","volume":"40","author":"Ren","year":"2024","journal-title":"Pharmacol. Clin. Chin. Materia Medica."},{"key":"B32","volume-title":"Evaluation of the efficacy of shufeng jiedu capsule in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease","author":"Shen","year":"2021"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.14066\/j.cnki.cn21-1349\/r.2023.0570","article-title":"Research progress on antiviral activities of glycyrrhizic acid and its derivatives","volume":"40","author":"Song","year":"2023","journal-title":"J. Shenyang Pharm. Univ."},{"key":"B34","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3969\/j.issn.1671-945X.2021.01.066","article-title":"Evaluation of the efficacy and safety of shufeng jiedu capsule combined with antibiotics in the treatment of CAP","volume":"19","author":"Tang","year":"2021","journal-title":"China Prescr. Drug"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.19540\/j.cnki.cjcmm.20200313.501","article-title":"Study on precise mechanism of Chinese patent medicine from perspective of activating data","volume":"45","author":"Wang","year":"2020","journal-title":"China J. Chin. Materia Medica"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.16025\/j.1674-1307.2020.11.027","article-title":"Observation on the efficacy of shufeng jiedu capsule combined with oseltamivir phosphate in the treatment of influenza complicated with acute tonsillitis","volume":"39","author":"Wang","year":"2020","journal-title":"Beijing J. Tradit. Chin. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"96","DOI":"10.13463\/j.cnki.jlzyy.2024.01.022","article-title":"Research progress on chemical constituents and pharmacological effects of bupleuri radix","volume":"44","author":"Wang","year":"2024","journal-title":"Jilin J. Traditional Chin. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.3969\/j.issn.1004-745X.2016.09.060","article-title":"Clinical efficacy of shufeng jiedu capsule combined with antibiotics in the treatment of community-acquired pneumonia","volume":"25","author":"Wei","year":"2016","journal-title":"Emerg. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"413","DOI":"10.19526\/j.cnki.1005-8915.20190509","article-title":"Clinical study of shufeng jiedu capsule combined with cefoperazone sodium and sulbactam sodium in the treatment of community-acquired pneumonia","volume":"26","author":"Wu","year":"2019","journal-title":"Biotechnol. Pharm."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.3969\/j.issn.1004-745X.2021.07.027","article-title":"Clinical observation of shufeng jiedu capsule combined with piperacillin-tazobactam in the treatment of acute exacerbation of chronic obstructive pulmonary disease complicated with community-acquired pneumonia","volume":"30","author":"Xia","year":"2021","journal-title":"Emerg. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.16025\/j.1674-1307.2017.03.022","article-title":"Clinical efficacy evaluation of shufeng jiedu capsule in the treatment of acute exacerbation of chronic bronchitis with wind-heat invading lung syndrome","volume":"36","author":"Xie","year":"2017","journal-title":"Beijing J. Tradit. Chin. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"676","DOI":"10.13288\/j.11-2166\/r.2015.08.012","article-title":"Randomized controlled double-blind trial of shufeng jiedu capsule in the treatment of wind-heat syndrome of acute upper respiratory tract infection","volume":"56","author":"Xu","year":"2015","journal-title":"Chin. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.3969\/j.issn.1004-745X.2019.10.035","article-title":"Effect of shufeng jiedu capsule on inflammatory factors and safety evaluation in patients with acute exacerbation of chronic obstructive pulmonary disease","volume":"28","author":"Yang","year":"2019","journal-title":"Emerg. Med. TCM."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3969\/j.issn.1004-745X.2022.07.039","article-title":"Effect of shufeng jiedu capsule combined with antibiotics on the efficacy and serum inflammatory factors in elderly patients with acute bacterial upper respiratory tract infection","volume":"31","author":"Yin","year":"2022","journal-title":"Emerg. Med. TCM."},{"key":"B46","doi-asserted-by":"publisher","first-page":"98","DOI":"10.13422\/j.cnki.syfjx.20240693","article-title":"Exploration of clinical precision positioning model for Chinese patent medicines based on spectrum-effect relationship of formula targets: a case study of qizhi tongluo capsule","volume":"30","author":"Yu","year":"2024","journal-title":"Chin. J. Exp. Traditional Med. Formulae"},{"key":"B47","doi-asserted-by":"publisher","first-page":"50","DOI":"10.13457\/j.cnki.jncm.2020.04.015","article-title":"Clinical efficacy of shufeng jiedu capsule in the treatment of acute upper respiratory tract infection and its effect on inflammatory factors","volume":"52","author":"Zhang","year":"2020","journal-title":"New J. Tradit. Chin. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"734","DOI":"10.13350\/j.cjpb.140816","article-title":"Effect of shufeng jiedu capsule on serum amyloid A in patients with acute viral upper respiratory tract infection","volume":"9","author":"Zhang","year":"2014","journal-title":"Chin. J. Pathobiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"151","DOI":"10.19335\/j.cnki.2096-1219.2022.3.051","article-title":"Observation on the efficacy of shufeng jiedu capsule in the treatment of acute tracheobronchitis with wind-heat invading lung syndrome","volume":"8","author":"Zhang","year":"2022","journal-title":"Smart Health"},{"key":"B50","first-page":"86","article-title":"Efficacy and serological evaluation of compound qinlan oral liquid in treating acute upper respiratory tract infection with wind-heat syndrome","volume":"6","author":"Zhang","year":"2022","journal-title":"Mod. Med. Health Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3969\/j.issn.1004-745X.2020.07.044","article-title":"Clinical observation of shufeng jiedu capsule in the treatment of acute upper respiratory tract infection (wind-heat syndrome)","volume":"29","author":"Zhao","year":"2020","journal-title":"J. Tradit. Chin. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"111","DOI":"10.13288\/j.11-2166\/r.2018.02.006","article-title":"Design method of parent protocol for clinical research on diseases with the same syndrome in traditional Chinese medicine","volume":"59","author":"Zhao","year":"2018","journal-title":"Chin. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.13193\/j.issn.1673-7717.2018.05.052","article-title":"Observation on the efficacy of shufeng jiedu capsule in the treatment of acute upper respiratory tract infection","volume":"36","author":"Zhao","year":"2018","journal-title":"Chin. Arch. Tradit. Chin. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.13288\/j.11-2166\/r.2011.18.002","article-title":"Constructing a new system of syndrome differentiation and treatment in traditional Chinese medicine with pathogenesis as the core: exploration of academic thoughts of professor zhou Zhongying, a master of Chinese medicine","volume":"52","author":"Zhou","year":"2011","journal-title":"J. Traditional Chin. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3969\/j.issn.1004-745X.2019.08.040","article-title":"Clinical observation of Shufeng Jiedu Capsule combined with moxifloxacin in the treatment of community-acquired pneumonia","volume":"28","author":"Zhou","year":"2019","journal-title":"Emerg. Med."},{"key":"B56","first-page":"4227","article-title":"Clinical observation of shufeng jiedu capsule combined with Western medicine in the treatment of acute exacerbation of chronic obstructive pulmonary disease with wind-heat invading lung syndrome","volume":"33","author":"Zhu","year":"2018","journal-title":"Chin. J. Tradit. Chin. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.7501\/j.issn.0253-2670.2022.11.034","article-title":"Research progress on the treatment of respiratory infectious diseases with shufeng jiedu capsule","volume":"53","author":"Zhu","year":"2022","journal-title":"Chin. Herb. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1602563\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T05:31:26Z","timestamp":1758173486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1602563\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":57,"alternative-id":["10.3389\/fphar.2025.1602563"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1602563","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"article-number":"1602563"}}